Proceeds support advancing wholly owned development candidate TRB-061, a novel TNFR2 agonist for the treatment of inflammatory diseases, through early clinical proof of concept Phase 1 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback